Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer

Clinical Endocrinology

Volumn 68, Issue 1, 2008, Pages 59-65

  Dockery, Frances ^a   Bulpitt, Christopher J ^a   Agarwal, Sanjiv ^a   Vernon, Clare ^a   Nihoyannopoulos, Petros ^a   Kemp, Martin ^b   Hooper, James ^b   Rajkumar, Chakravarthi ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIANDROGEN; BICALUTAMIDE; BIOLOGICAL MARKER; ESTRADIOL; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; HORMONE RECEPTOR BLOCKING AGENT; TESTOSTERONE;

AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CANCER HORMONE THERAPY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE RELAXATION; HEART STROKE VOLUME; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; WAIST HIP RATIO;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; ESTRADIOL; GOSERELIN; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NITRILES; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; TESTOSTERONE; TOSYL COMPOUNDS;

EID: 36949026378     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02999.x     Document Type: Article

References (31)

1. Labrie, F., Dupont, A., Belanger, A., St-Arnaud, R., Giguere, M., Lacourciere, Y., Emond, J. Monfette, G. (1986) Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocrine Reviews, 7, 67 74.
2. Wirth, M.P., See, W.A., McLeod, D.G., Iversen, P., Morris, T. Carroll, K. Casodex Early Prostate Cancer Trialists' Group (2004) Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. Journal of Urology, 172, 1865 1870.
3. Iversen, P., Johansson, J.E., Lodding, P., Lukkarinen, O., Lundmo, P., Klarskov, P., Tammela, T.L., Tasdemir, I., Morris, T. Carroll, K. Scandinavian Prostatic Cancer Group (2004) Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. Journal of Urology, 172, 1871 1876.
4. Waxman, J. Mazhar, D. (2003) How are we looking after prostate cancer? QJM, 96, 75 79.
5. Dockery, F., Bulpitt, C.J., Agarwal, S., Donaldson, M. Rajkumar, C. (2003) Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clinical Science, 104, 195 201.
6. Smith, J.C., Bennett, S., Evans, L.M., Kynaston, H.G., Parmar, M., Mason, M.D., Cockcroft, J.R., Scanlon, M.F. Davies, J.S. (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. Journal of Clinical Endocrinology and Metabolism, 86, 4261 4267.
7. Wu, F.C. von Eckardstein, A. (2003) Androgens and coronary artery disease. Endocrine Reviews, 24, 183 217.
8. Rosano, G.M., Cornoldi, A. Fini, M. (2005) Effects of androgens on the cardiovascular system. Journal of Endocrinological Investigation, 28, 32 38.
9. Jeppensen, L.L., Jorgensen, H.S., Nakayama, H., Raaschou, H.O., Olsen, T.S. Winther, K. (1996) Decreased serum testosterone in men with acute ischemic stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 16, 749 754.
10. Hak, A.E., Witteman, J.C., de Jong, F.H., Geerlings, M.I., Hofman, A. Pols, H.A. (2002) Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. Journal of Clinical Endocrinology and Metabolism, 87, 3632 3639.
11. Haddad, R.M., Kennedy, C.C., Caples, S.M., Tracz, M.J., Bolona, E.R., Sideras, K., Uraga, M.V., Erwin, P.J. Montori, V.M. (2007) Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clinic Proceedings, 82, 29 39.
12. Marsh, J.D., Lehmann, M.H., Ritchie, R.H., Gwathmey, J.K., Green, G.E. Schiebinger, R.J. (1998) Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation, 98, 256 261.
13. Nahrendorf, M., Frantz, S., Hu, K., Tomaszewski, M., Schueuermann, H., Kaiser, R., Jazbutyte, V., Beer, S., Bauer, W., Neubauer, S., Ertl, G., Allolio, B. Callies, F. (2003) Effect of testosterone on post-myocardial infarction remodelling and function. Cardiovascular Research, 57, 370 378.
14. Svartberg, J., von Muhlen, D., Schirmer, H., Barrett-Connor, E., Sundfjord, J. Jorde, R. (2004) Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. European Journal of Endocrinology, 150, 2004.
15. Dobrzycki, S., Serwatka, W., Nadlewski, S., Korecki, J., Jackowski, R., Paruk, J., Ladny, J.R. Hirnle, T. (2003) An assessment of correlations between endogenous sex hormone levels and the extensiveness of coronary heart disease and the ejection fraction of the left ventricle in males. Journal of Medical Investigation, 50, 162 169.
16. Malkin, C.J., Pugh, P.J., West, J.N., van Beek, E.J., Jones, T.H. Channer, K.S. (2006) Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. European Heart Journal, 27, 57 64.
17. Sudhir, K. Komesaroff, P.A. (1999) Clinical review 110: Cardiovascular actions of estrogens in men. Journal of Clinical Endocrinology and Metabolism, 84, 3411 3415.
18. Sader, M.A., McCredie, R.J., Griffiths, K.A., Wishart, S.M., Handelsman, D.J. Celermajer, D.S. (2001) Oestradiol improves arterial endothelial function in healthy men receiving testosterone. Clinical Endocrinology, 54, 175 181.
19. Wang, T.J., Larson, M.G., Levy, D., Benjamin, E.J., Leip, E.P., Omland, T., Wolf, P.A. Vasan, R.S. (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. New England Journal of Medicine, 350, 655 663.
20. Kragelund, C., Gronning, B., Kober, L., Hildebrandt, P. Steffensen, R. (2005) N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. New England Journal of Medicine, 352, 666 675.
21. Heeschen, C., Hamm, C.W., Mitrovic, V., Lantelme, N.H. White, H.D. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators (2004) N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation, 110, 3206 3212.
22. Kistorp, C., Raymond, I., Pedersen, F., Gustafsson, F., Faber, J. Hildebrandt, P. (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. Journal of the American Medical Association, 293, 1609 1616.
23. McKie, P.M., Rodeheffer, R.J., Cataliotti, A., Martin, F.L., Urban, L.H., Mahoney, D.W., Jacobsen, S.J., Redfield, M.M. Burnett, J.C. Jr. (2006) Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension, 47, 874 880.
24. Maffei, S., Del Ry, S., Prontera, C. Clerico, A. (2001) Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clinical Science, 101, 447 453.
25. Karjalainen, A.H., Ruskoaho, H., Vuolteenaho, O., Heikkinen, J.E., Backstrom, A.C., Savolainen, M.J. Kesaniemi, Y.A. (2004) Effects of estrogen replacement therapy on natriuretic peptides and blood pressure. Maturitas, 47, 201 208.
26. Galasko, G.I., Lahiri, A., Barnes, S.C., Collinson, P. Senior, R. (2005) What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? European Heart Journal, 26, 2269 2276.
27. El-Gehani, F., Tena-Sempere, M., Ruskoaho, H. Huhtaniemi, I. (2001) Natriuretic peptides stimulate steroidogenesis in the fetal rat testis. Biology of Reproduction, 65, 595 600.
28. Khurana, M.L. Pandey, K.N. (1993) Receptor-mediated stimulatory effect of atrial natriuretic factor, brain natriuretic peptide, and C-type natriuretic peptide on testosterone production in purified mouse Leydig cells: activation of cholesterol side-chain cleavage enzyme. Endocrinology, 133, 2141 2149.
29. Chang, A.Y., Abdullah, S.M., Jain, T., Stanek, H.G., Das, S.R., McGuire, D.K., Auchus, R.J. de Lemos, J.A. (2006) Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. Journal of the American College of Cardiology, 49, 109 116.
30. Wold Knudsen, C., Vik-Mo, H. Omland, T. (2005) Blood haemoglobin is an independent predictor of B-type natriuretic peptide (BNP). Clinical Science, 109, 69 74.
31. Wu, A.H., Omland, T., Wold Knudsen, C., McCord, J., Nowak, R.M., Hollander, J.E., Duc, P., Storrow, A.B., Abraham, W.T., Clopton, P., Maisel, A.S. McCullough, P.A. Breathing Not Properly Multinational Study Investigations (2005) Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study. American Journal of Hematology, 80, 174 180.